Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Priya Nigam

Why BofA Sees 'Better Entry Point' In Ginkgo Bioworks Stock

Ginkgo Bioworks Holdings Inc (NYSE:DNA) is “at the forefront of the rising SynBio wave, a market we think holds much long-term promise,” according to BofA Securities.

The Ginkgo Bioworks Analyst: Derik de Bruin initiated coverage of Ginkgo Bioworks with a Buy rating and $8 price target.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.